Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

BEAM-101 demonstrated robust and durable increases in fetal hemoglobin and reductions in sickle hemoglobin, showcasing its potential effectiveness in treating sickle cell disease. The safety ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Treatment with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF ... genetically modified cell therapy for the treatment of severe sickle cell disease (SCD).

Currently in preclinical development, IMMvention’s orally dosed BACH1 inhibitors have the potential to increase fetal hemoglobin ... address unmet needs in sickle cell disease and beyond ...

The knowledge and awareness of genotype must start from the parents, adding that this understanding would aid the transfer of ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...